Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1307
- Registration Number
- NCT01340027
- Locations
- 🇫🇷
FR33111, Paris Cedex 13, France
🇸🇰SK42109, Banska Bystrica, Slovakia
🇸🇰SK42106, Piestany, Slovakia
A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill
- Conditions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01297179
A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously
- Conditions
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 41
- Registration Number
- NCT01297192
A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex
- Conditions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT01285596
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 321
- Registration Number
- NCT01284309
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.
- Conditions
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01284868
A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 352
- Registration Number
- NCT01199523
Study of the Effect of Food on the Pharmacokinetics of Mirabegron
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 76
- Registration Number
- NCT00939757
Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 91
- Registration Number
- NCT00940121
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2030
- Registration Number
- NCT00912964
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.